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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Cytochrome P450 (CYP) 2B6 polymorphisms, particularly
c.516G→T, are strongly associated with plasma
efavirenz concentrations, but do not entirely explain
interindividual variability in efavirenz exposure.
• In vitro data suggest that CYP2A6 is involved in the
metabolism of efavirenz.
• Rifampicin can induce the function and activity of the
main metabolizing for efavirenz and causes small
(22–26%) reductions in efavirenz area under the curve
during co-administration, although with wide
interindividual variability.
WHAT THIS STUDY ADDS
• Identifies CYP2B6 516G→T polymorphism and carriers
of CYP2A6*9B and/or *17 variants as independent
predictors of efavirenz mid-dose concentration in
human immunodeficiency virus-infected patients.
• Factors such as concurrent therapy with
rifampicin-containing tuberculosis regimen, gender and
body mass index had no a significant influence on
efavirenz mid-dose concentration.
• Provides in vivo evidence that CYP2A6 is likely to be
involved in the metabolism of efavirenz.
AIMS
Interindividual variability in efavirenz pharmacokinetics is not entirely explained by the
well-recognized CYP2B6 516G→T single nucleotide polymorphism. The aim of this study
was to determine whether polymorphisms in the CYP2A6 gene can be used to enhance the
predictability of efavirenz concentrations in human immunodeficiency virus (HIV)-infected
native African patients.
METHODS
Mid-dose efavirenz plasma concentrations were determined at 4 and 8 weeks following
initiation of antiretroviral therapy in 65 HIV-infected Ghanaian patients. Selected CYP2B6
and CYP2A6 genotypes were determined by commercial 5′-nuclease assays. Relationships
between averaged 4- and 8-week mid-dose efavirenz concentrations, demographic
variables and genotypes were evaluated by univariate and multivariate statistical
approaches including gene–gene interactions.
RESULTS
CYP2B6 c.516G→T, CYP2B6 c.983T→C, CYP2A6*9B and CYP2A6*17 allele frequencies were
45, 4, 5 and 12%, respectively. Rifampicin therapy, gender, age and body mass index had no
significant influence on efavirenz mid-dose concentrations. Median efavirenz concentrations
were more than five times higher (P < 0.001) in patients with CYP2B6 c.516TT genotype
compared with GG and GT genotypes. Although none of the CYP2A6 genotypes was
associated with altered efavirenz concentrations individually, CYP2A6*9B and/or CYP2A6*17
carriers showed a 1.8 times higher median efavirenz concentration (P = 0.017) compared
with noncarriers. Multiple linear regression analysis indicated that the CYP2B6 c.516G→T
polymorphism and CYP2A6 slow-metabolizing variants accounted for as much as 36 and
12% of the total variance in efavirenz concentrations, respectively.
CONCLUSIONS
Our findings support previous work showing efavirenz oxidation by CYP2A6, and suggest
that both CYP2A6 and CYP2B6 genotyping may be useful for predicting efavirenz plasma
concentrations.
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Introduction
Efavirenz is an essential component of the preferred non-
nucleoside reverse transcriptase regimen for the initial
treatment of human immunodeficiency virus (HIV) infec-
tion [1, 2]. Despite the potency and favourable tolerability
of efavirenz-based regimens, some patients develop
treatment-limiting toxicity or fail to achieve durable viral
load suppression [3, 4]. Efavirenz plasma concentrations
>4 mg/ml have been associated with an increased risk of
adverse central nervous system effects, whereas concen-
trations <1 mg/ml have been associated with virological
failure [5, 6]. However, other studies, including the large
‘double non-nucleoside (2NN)’ study, have failed to find
any significant relationships between efavirenz plasma
concentrations and virological failure [7, 8]. The fixed daily
dose of 600 mg efavirenz for adults results in significant
interindividual variability in plasma concentrations and
clinical effects [5, 6, 9]. Consequently, it is of substantial
clinical importance to identify factors that contribute
to interindividual variability in efavirenz disposition, as
efavirenz-based therapy is the preferred regimen in
patients with tuberculosis (TB)/HIV co-infection receiving
rifampicin-containing therapy in settings where rifabutin
is not available [10, 11].
The main enzyme that metabolizes efavirenz is cyto-
chrome P450 2B6 (CYP2B6) [12].The CYP2B6 gene is highly
polymorphic, and genotyping for functional single nucle-
otide polymorphisms (SNPs) has proven to be useful in the
prediction of efavirenz pharmacokinetics [13, 14]. In par-
ticular, the CYP2B6 c.516G→T is a common polymorphism
(21–38% allele frequency),[15] that has been consistently
associated with reduced enzyme activity and higher
efavirenz exposure in studies of different populations with
varied racial and ethnic backgrounds [13, 15–18].The more
recently described CYP2B6 c.983T→C variant with up to
10% allele frequency is also associated with lower enzyme
activity and higher efavirenz concentrations,but appears to
be exclusively found in populations of African descent [14,
19, 20]. Other CYP2B6 polymorphisms that have been iden-
tified either have minimal impact on efavirenz metabolism,
or are relatively rare (i.e. <5% allele frequency) [15].
Not all interindividual variability in efavirenz pharma-
cokinetics appears to be explained by CYP2B6 genetic vari-
ants [15], suggesting that there may be polymorphisms in
other genes that influence efavirenz disposition. In addi-
tion to CYP2B6, several other CYPs, including CYP1A2,
CYP2A6, CYP2C9, CYP3A4 and CYP3A5, may contribute to
efavirenz metabolism [12, 16]. Several other studies have
shown that polymorphisms in the CYP3A4 and CYP3A5
genes do not influence efavirenz plasma concentrations
[21–23]. Polymorphisms in CYP1A2 and CYP2C9 either have
no established association with phenotype [24], or, if asso-
ciated, the variants are relatively rare in Black African popu-
lations [25]. However, several CYP2A6 genetic variants
associated with reduced enzyme activity are relatively
common in Black populations [26–28]. Specifically, the
CYP2A6*9B allele with a mutation in the TATA box (T–48G)
and CYP2A6*17 with the amino acid substitution (V365M)
are associated with substantially decreased enzyme activ-
ity with reported allele frequencies of 5.7 and 9.4%, respec-
tively, in Black populations [26–28]. The influence of these
polymorphisms on efavirenz plasma concentrations in
HIV-infected patients has yet to be reported.Consequently,
in the present study we determined whether assaying for
slow metabolizer CYP2A6 genetic variants can enhance the
predictability of efavirenz plasma concentrations over that
of CYP2B6 genotype alone in a cohort of HIV-infected Gha-
naian patients receiving efavirenz-based therapy.
Methods
Study population and treatment regimens
Seventy-four HIV-infected patients with CD4 count 250
cells ml-1 were enrolled between January 2005 and Decem-
ber 2007 in a pilot trial of a simplified once-daily antiretro-
viral therapy. Thirty-four (46%) of the patients also had TB
co-infection. Enrolled patients were naive to antiretroviral
therapy, aged 18 years and had no other opportunistic
conditions.The once-daily antiretroviral regimen consisted
of didanosine-buffered tablets 400 mg (body weight
>60 kg) or 300 mg (body weight <60 kg), lamivudine
300 mg, and efavirenz 600 mg. Adherence, assessed
monthly by pill count and patient self-report, was found to
be good in all patients except for one (not included in the
final analysis), who had undetectable antiretroviral drug
concentrations.
In the patients with TB, antiretroviral therapy was initi-
ated 2–8 weeks after the start of rifampicin-containing
TB therapy. Tuberculosis therapy consisted of daily self-
administration of isoniazid 5 mg kg-1 (maximum 300 mg)
daily, rifampicin 10 mg day-1 (maximum 750 mg) daily,
pyrazinamide 20–25 mg kg-1 (maximum 2000 mg) daily
and ethambutol 15–20 mg kg-1 (maximum 1600 mg)
daily for 2 months in the induction phase. Patients enrolled
before 1 July 2007 received daily isoniazid and ethambutol
for 6 months in the continuation phase of therapy and
those enrolled after that date received daily isoniazid and
rifampicin for 4 months in accordance with the Ghana
National TB treatment guidelines at the time of the study.
Also, after 1 July 2007, all patients received a fixed dose
combination tablet of isoniazid 75 mg, rifampicin 150 mg,
pyrazinamide 400 mg and ethambutol 275 mg, isoniazid
75 mg and rifampicin 150 mg in the induction and continu-
ation phases, respectively. The study was reviewed and
approved by the Institutional Review Board of the Nogou-
chi Memorial Institute for Medical Research (Legon,Ghana).
Informed written consent was obtained from all patients.
Study procedures
Clinical assessments including a medical history, physical
examination and baseline CD4 cell counts and HIV RNA
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were performed at study entry and at scheduled
follow-up visits. Antiretroviral therapy was self-
administered at night and a mid-dose blood sampling
was obtained at weeks 4 and 8 of therapy. Patients were
asked to record the time of the evening dose before
pharmacokinetic sampling, and samples were drawn at
approximately 12 h after the efavirenz dose was taken.
Plasma samples were stored at -70°C until testing. Mid-
dose sampling (i.e. sampling done between doses, usually
between 8–20 h postdose) is frequently used in clinical
studies of efavirenz disposition for patient convenience
since the drug is invariably taken at bedtime to minimize
central nervous system side-effects during the day [5, 29].
We have recently reported that mid-dose efavirenz con-
centrations are highly correlated with efavirenz area
under the curve (AUC) values when measured at steady
state, which is consistent with the relatively prolonged
half-life of this drug [18]. In HIV-infected patients,
efavirenz steady-state concentrations are reached in 6–10
days [30]. Patients who had pharmacokinetic sampling
performed during concurrent administration with
rifampicin-containing TB therapy or for up to 1 week after
stopping this therapy (two patients) were classified as
receiving rifampicin-containing TB therapy. This was
based on the known effects of rifampicin on increasing
CYP activity, which are estimated to occur with 6 days of
therapy initiation and to dissipate by 2 weeks after dis-
continuation [31].
Drug concentration assays
Efavirenz concentrations in plasma were measured using
a validated high-performance liquid chromatography/
ultraviolet method [32]. This method was validated over a
range of 15–10 000 ng ml-1 and is accurate (90.4–110.5%)
with intraday and interday precision of 2.3–8.3%. All ana-
lytical work was performed by the University of North
Carolina Center for AIDS Research Clinical Pharmacology
and Analytical Chemistry Core, which is Clinical Laboratory
Improvement Amendments certified and participates in
quarterly national and international external proficiency
testing [33, 34].
Genotyping and copy number assays
Subjects were genotyped for CYP2B6 c.516G→T (Q172H,
rs3745274), c.983T→C (I328T, rs28399499), CYP2A6 *9B,
(g.1836G→T, rs8192726, which is in linkage disequilib-
rium with the *9B defining TATA box mutation g.-48T→G,
rs28399433), and CYP2A6 *17 (g.5065G→A, c.1093G→A,
M365V, rs28399454) using the fluorometric 5′ nuclease
genotyping assay (TaqMan Assays; Applied Biosystems,
Foster City, CA, USA). CYP2A6 gene copy number variation
was also performed using the gene copy number
assay (TaqMan®; Applied Biosystems) according to the
manufacturer’s instructions. All reactions were performed
in an ABI PRISM 7300 HT system (Applied Biosystems),
and results were verified by two investigators (A.K.,
M.H.C.). We performed direct sequencing to confirm the
genotyping results in one patient with CYP2B6 516TT
genotype, who had a relatively low efavirenz concentra-
tion, and in all the six patients with CYP2B6 983TC
genotype.
Statistical analyses
Statistical analyses were performed using Sigmplot 11
software, which incorporates a comprehensive statistical
analysis module (Systat, San Jose, CA, USA). Unless other-
wise indicated, P < 0.05 was considered to be statistically
significant. It was necessary to rank transform efavirenz
concentration data to achieve data normality and equal
variance. The relationship between efavirenz concentra-
tions determined at 4 weeks and at 8 weeks of therapy
was evaluated by Spearman rank order correlation analy-
sis and compared by Mann–Whitney rank sum test.
Univariate analyses of effects of patient demographics
and genotypes on mean efavirenz mid-dose concentra-
tions were assessed by Mann–Whitney rank sum test
(gender, rifampin use, alcohol use, and for two genotype
groups), analysis of variance (ANOVA) (for three genotype
groups) or by linear regression [for age, body weight and
body mass index (BMI)]. Two-way ANOVA, which incorpo-
rates an interaction model, was also used to investigate
effects of CYP2B6 516G→T genotype and CYP2A6 vari-
ants. In instances where the ANOVA (one-way or two-way)
indicated a significant effect (P < 0.05), post hoc multiple
pair-wise comparison testing was performed using the
Student–Newman–Keuls method to identify groups that
were significantly different from each other. Finally, mul-
tiple linear regression analysis was used to construct a
predictive model using patient demographic factors and
genotypes as independent variables and efavirenz con-
centrations as the dependent variable. Dichotomous vari-
ables, including gender, rifampin use, alcohol use, CYP2A6
variant, and CYP2B6 983T→C genotype were coded as 0
or 1, while age, body weight and BMI were included as
continuous variables. Two variables were used to describe
CYP2B6 516G→T genotype, coded as GG/GT = 0 and TT =
1 for the recessive genetic model and also as GG = 0 and
GT/TT = 1 for the dominant genetic model. This also
allowed for the additive genetic model if both CYP2B6
516G→T variables were found to be significant. Using an
automated method implemented in Sigmaplot 11, a
minimal multiple linear regression model was then iden-
tified by stepwise removal of nonsignificant variables
until all remaining independent variables had coefficients
with P-values < 0.05. The percentage of variance
explained by the model was based on the coefficient of
determination (R2). The contribution of each independent
variable (expressed as a percentage) to the total
explained variance was derived from the standardized
regression coefficients, which had been normalized to the
total explained variance.
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Results
Study population
Seventy-four HIV-infected patients treated with efavirenz-
containing highly active antiretroviral therapy were initially
enrolled in the study.Of these,nine were excluded from the
final genotype–phenotype analysis either because they
had died before study completion (n = 5),had discontinued
the study for other reasons prior to pharmacokinetic sam-
pling (n = 2), or had undetectable concentrations of all
antiretroviral drugs or incomplete data (n = 2).
Patient demographics and efavirenz plasma
concentrations
Of the 65 patients included in final analysis, the mean
(SD) age was 38  8 years, baseline body weight was 54
 12 kg, and BMI was 19.5  4.1. Thirty-six patients (55%)
were female, nine (14%) reported alcohol use, and 19
(29%) were receiving concurrent rifampicin-containing TB
therapy at the time of efavirenz sampling. The mean time
of pharmacokinetic sampling was 14.1  1.1 h postdose,
median 13.9 h (range 12–18 h) postdose.
As shown in Figure 1, efavirenz concentrations in
plasma samples collected at 4 weeks and 8 weeks follow-
ing initiation of antiretroviral therapy were well correlated
(Spearman correlation coefficient Rs = 0.68; P < 0.001).
Values were also equally clustered around the line of iden-
tity consistent with steady-state pharmacokinetics being
reached by 4 weeks and maintained until the 8 weeks
sampling time.The median [interquartile range (IQR)] mid-
dose efavirenz plasma concentrations at 4 weeks and 8
weeks were 1763 (1251–2795) ng ml-1 and 1609 (1244–
2465) ng ml-1, respectively, and were statistically indistin-
guishable (P = 0.40; Mann–Whitney rank sum test).
Consequently, to simplify the presentation of results of
further analyses, 4-week and 8-week values were averaged
for each subject resulting in median (IQR) mid-dose
efavirenz plasma concentrations of 1597 (1279–
2803) ng ml-1 for all 65 subjects. This approach was also
supported by preliminary analyses, which showed essen-
tially identical results for the results reported below
regardless of whether 4-week, 8-week, or averaged results
were used.
None of the patient demographic variables examined
including age (P = 0.47; linear regression), BMI (P = 0.068;
linear regression), gender (P = 0.98; Mann–Whitney rank
sum test) or alcohol use (P = 0.42; Mann–Whitney rank sum
test) was associated with altered mid-dose efavirenz con-
centrations (data not shown). Furthermore [median (IQR)]
efavirenz concentrations in patients receiving rifampicin-
containing TB therapy [1628 (1224–2315) ng ml-1] were
not different from levels in patients that were not receiving
this additional therapy [1582 (1360–3020) ng ml-1] (P =
0.86; Mann–Whitney rank sum test).
CYP2B6 and CYP2A6 polymorphisms
Variant allele frequencies for the 65 study patients were 45,
4, 5 and 12% for CYP2B6 c.516G→T, CYP2B6 c.983T→C,
CYP2A6*9B and CYP2A6*17, respectively. The numbers of
subjects with each individual genotype are given in
Table 1. No subjects were identified who were homozy-
gous variant for CYP2B6 c.983T→C. We also determined
that all subjects had two copies of the CYP2A6 gene based
on a CYP2A6 gene copy number variation assay.
CYP2B6 and CYP2A6 genotype effects on
efavirenz exposure
Univariate analyses Figure 2 shows the distribution of
efavirenz plasma levels stratified by CYP2B6 and CYP2A6
genotypes, while the results of univariate statistical analy-
ses of these genotypes are given in Table 1. As expected,
CYP2B6 516G→T genotype was significantly associated
with decreased efavirenz concentration (P < 0.001, ANOVA).
Median efavirenz concentrations for CYP2B6 516TT geno-
type was at least five times higher than both the CYP2B6
516GT (P < 0.001) and 516GG (P < 0.001) genotype groups.
The median efavirenz concentration for CYP2B6 516GT
genotype was about 1.2 times higher than values for the
516GG genotype (P > 0.027). None of the other individual
genotypes evaluated, including CYP2B6 c.983T→C (P =
0.61), CYP2A6*9B (P = 0.07) and CYP2A6*17 (P = 0.15), was
individually associated with altered efavirenz concentra-
tions. However, when both CYP2A6 slow metabolizer vari-
ants were considered together, the median efavirenz
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Figure 1
Correlation of mid-dose efavirenz concentrations in plasma from 65
human immunodeficiency virus-infected Ghanaian patients measured 4
weeks (abscissa) and 8 weeks (ordinate) after commencing treatment.
Shown are the Spearman correlation coefficient (Rs) and associated
P-value for the correlation analysis, and the line of identity representing
perfect correlation
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was 1.8 times higher than among individuals without
either of these variants (P = 0.017).
Bivariate analysis Two-way ANOVA was then used to
control for the CYP2B6 516G→T genotype effect and
evaluate whether there was any additional influence from
the CYP2A6 slow metabolizer variants, including evaluation
of possible gene–gene interactions. As shown in Figure 3,
CYP2A6 slow metabolizer variants were independently
associated with higher efavirenz concentrations regardless
of CYP2B6 516G→T genotype (P < 0.001 for CYP2B6
516G→T genotype; P = 0.028 for CYP2A6 variants; P = 0.55
for interaction). Post hoc analysis of the CYP2A6 variant
effect within each of the CYP2B6 516G→T genotype
groups using the Student–Newman–Keuls method
showed that patients with CYP2B6 516GT genotype who
also had CYP2A6 variants had significantly higher median
efavirenz concentration than noncarriers (2694 vs. 1448;
P = 0.01) (Figure 3). Trends for higher median efavirenz
concentrations in CYP2A6 variant carriers compared with
noncarriers were also observed in the two other CYP2B6
516G→T genotype groups, although the differences did
not achieve statistical significance (P > 0.05).
Of note in this analysis were three patients (indicated
in Figure 3) that did not have the slow metabolizer CYP2B6
516TT genotype and yet had relatively high efavirenz
concentrations (>4000 ng ml-1). Of these, one individual
(patient 159 with CYP2B6 516GG genotype) was homozy-
gous for the CYP2A6*17 variant, another individual (patient
158 with CYP2B6 516GT genotype) carried both the
CYP2A6*9B and *17 alleles, and the other individual
(patient 13 with CYP2B6 516GT genotype) was heterozy-
gous for both the CYP2A6*9 and CYP2B6 983T→C variants.
Multiple linear regression analysis Stepwise backward
multiple linear regression analysis was then performed to
identify the minimum set of independent variables that
are predictive of efavirenz plasma concentrations, and also
determine the relative contribution of these variables
to overall variability in efavirenz concentrations. Variables
entered into the initial model included sex, age, weight,
BMI, alcohol use, rifampin treatment, CYP2B6 516G→T
genotypes, 983T→C genotype, as well as CYP2A6 slow
metabolizer variant carrier status. Only three independent
variables remained in the final model with P < 0.05, includ-
ing CYP2B6 516TT genotype (standardized regression
coefficient = 0.51; P < 0.001), CYP2B6 516GG genotype
(standardized regression coefficient = 0.24; P = 0.017), and
CYP2A6 variants (standardized regression coefficient =
0.25; P = 0.008).The coefficient of determination (R2) for the
regression was 0.48, indicating that 48% of the total vari-
ance in efavirenz concentrations was explained by the
model. A comparison of the standardized regression coef-
ficients indicated that CYP2B6 516TT, CYP2B6 516GG and
CYP2A6 variant genotypes accounted for 24, 12 and 12%
(respectively) of the total variance in efavirenz plasma con-
centrations. Inclusion of both CYP2B6 516TT and CYP2B6
516GG genotypes in the final model is consistent with an
additive genetic model with all CYP2B6 c.516G→T geno-
types accounting for 36% of the total variance. We found
no significant association (P > 0.05) between efavirenz
plasma concentrations and patient age, gender, weight,
BMI, alcohol use, or rifampicin-containing TB therapy.
Discussion
In this study, we have identified CYP2A6 slow metabolizer
variants (*9B and/or *17) as independent predictors of
efavirenz plasma concentration beyond that provided
by the well-known CYP2B6 516G→T polymorphism. This
finding suggests that CYP2A6 genotyping may be useful in
enhancing the accuracy of prediction of efavirenz concen-
trations in HIV-infected patients over that of CYP2B6
516G→T alone. Our published data have been confirmed
by a recent report (unpublished conference abstract)
demonstrating an association between slow metabolizer
CYP2A6 alleles and increased efavirenz concentrations in
169 patients in the Swiss HIV Cohort [35]. However, in that
study the effect of the CYP2A6*7, *9 and/or *17 alleles was
observed only in patients with CYP2B6 slow metabolizer
genotypes [35], which contrasts with our study, which
showed an effect regardless of CYP2B6 genotype as
reflected by a lack of significant gene–gene interaction in
Table 1
Impact of CYP2B6 and CYP2A6 polymorphisms on mid-dose efavirenz






GG 22 (30%) 1 282 (1089–1901)†
GT 38 (51%) 1 560 (1379–2205)†
TT 14 (19%) 8 320 (6085–10 673)†
CYP2B6 c.983T,C 0.88
TT 59 (91%) 1 567 (1274–2649)
TC 6 (9%) 1 832 (1334–3102)
CYP2A6*9B (g.1836G,T) 0.07
TT 59 (91%) 1 562 (1265–2356)
TG 5 (8%) 3 102 (1568–4712)
GG 1 (1%) 10 726
CYP2A6*17 (c.1093G,A) 0.15
GG 51 (78%) 1 557 (1274–2334)
GA 12 (19%) 1 994 (1325–4063)
AA 2 (3%) 6 374 (4220–8529)
CYP2A6 *9B or *17 0.017
Reference 47 (72%) 1 516 (1242–2084)
Variant carrier 18 (28%) 2 694 (1597–5943)
*Values are the average of efavirenz concentrations determined at 4 and 8 weeks
in each patient; note that four patients had missing efavirenz concentration data
at week 4, and seven patients had missing concentration data at week 8. †P <
0.001 for 516TT vs. GT, P < 0.001 for 516TT vs. GG, P = 0.027 for 516GG vs. GT
groups determined by Student–Newman–Keuls test.
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the two-way ANOVA analysis. However, we did observe the
greatest CYP2A6 variant effect in patients with CYP2B6
516GT genotype (see Figure 2). The reasons for the differ-
ences between these two studies are not immediately
apparent but could be related to differences in popula-
tions, as our study enrolled only native Africans, whereas
the other study was primarily of Whites. There were also
differences in use of concurrent medications, as 19 of our
18000
20000
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Figure 2
Influence of CYP2B6 c.516G→T and CYP2B6 c.983T→C polymorphisms (A) and of CYP2A6*9 and CYP2A6*17 polymorphisms (B) on efavirenz mid-dose
concentrations (average of 4-week and 8-week samples) in human immunodeficiency virus (HIV) and HIV/tuberculosis co-infected patients in Ghana.
Differences between groups were examined by Mann–Whitney rank sum test (two genotype groups) or by ANOVA (three genotype groups) with post hoc
Student–Newman–Keuls pair-wise multiple comparisons testing
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patients with HIV/TB co-infection also received anti-TB
drugs, which may have altered CYP gene expression.
In vitro studies have demonstrated that recombinant
CYP2A6 is capable of hydroxylating efavirenz at both the
8- and 14- positions, although the activity of CYP2A6
compared with CYP2B6 in these reactions is admittedly
low [12]. Furthermore, the rate of efavirenz 7-hydroxylation
measured in a human liver bank was most highly corre-
lated with CYP2A6 immunoquantified protein and cou-
marin hydroxylation, a CYP2A6-selective enzyme activity
[16]. Unfortunately, as yet there are no reports of the quan-
titative contribution of CYP2A6 to efavirenz metabolism
in human liver, such as through use of isoform-specific
CYP2A6 chemical or antibody inhibitors. Nevertheless, the
results of the present study showing higher efavirenz con-
centrations in patients with CYP2A6 slow metabolizer
alleles support a role for CYP2A6 in efavirenz metabolism
in patients.
We also examined the effect of the CYP2B6 983TC geno-
type on efavirenz exposure but found no significant
relationship,possibly because of the small size of our popu-
lation, which contained no homozygous variant individu-
als. Recent clinical studies suggest that high efavirenz
concentrations are more likely to occur in patients who are
CYP2B6 983T→C homozygous variant [14] or in patients
who are heterozygous for CYP2B6 983T→C and are het-
erozygous for CYP2B6 516G→T [15]. The CYP2B6 983T→C
polymorphism results in a I328T amino acid substitution
and has been considered a null allele since recombinant
expression in COS-1 cells results in complete lack of CYP2B6
protein and activity [19].However,CYP2B6 983T→C has also
been reported to occur as an allele (CYP2B6*16) with
CYP2B6 c.785A→G (results in amino acid substitution
K262R),and expression of CYP2B6*16 cDNA constructs with
both these mutations results in somewhat decreased (but
not absent) enzyme protein and activity [36].
Our data are consistent with previous reports of a high
frequency of CYP2B6 516G→T variant alleles in native Afri-
cans [18, 37], but a somewhat lower frequency of CYP2B6
983T→C genetic variation [20]. The frequency of the
CYP2A6*17 variant allele of 11% in our population was
similar to that among Black subjects recruited in the USA
and Asia [26,28].CYP2A6*9B variation in our population was
also similar to that reported among healthy Ghanaian
subjects [27]. Overall, nearly one-third of our patients had
CYP2A6*9B and/or CYP2A6*17 variants, and if the associa-
tion between CYP2A6 genetic variation and efavirenz
disposition is confirmed in other studies, genotyping
for CYP2A6 variation would help improve pharmacokinetic
prediction afforded by CYP2B6 516G→T SNP screening
alone.
As a CYP2B6 enzyme inducer, rifampicin co-
administration would be expected to enhance efavirenz
clearance and reduce plasma concentrations. However, in
this study we found no difference in efavirenz concentra-
tions between patients receiving rifampicin-containing TB
therapy and those not receiving this therapy. These data
are reassuring, as HIV/TB co-infection is common in sub-
Saharan Africa, and efavirenz-based antiretroviral therapy
is often needed in patients receiving rifampicin-containing
TB treatment. It is important to recognize that this was not
a crossover study and so results could have been con-
founded by population differences. However, available
published studies in which efavirenz concentrations were
evaluated with and without rifampicin-containing treat-
ment at different times in the same patients have also
reported no significant differences in efavirenz concentra-
tions [38, 39]. In the South African study, the geometric
mean efavirenz trough concentration on rifampicin was
1730 ng ml-1 (range 345–27 179) and 1377 ng ml-1 (range
572–3975) off rifampicin (P = 0.55) [38]. The study by
López-Cortés et al., in which they evaluated the effect of
rifampicin on efavirenz pharmacokinetic parameters in a
subgroup, also did not reach statistical significance (P >
0.05) [39]. Although the mean efavirenz AUC declined by
22% during co-administration with rifampicin (P > 0.05) in
the aforementioned study, the change in efavirenz AUC
ranged from a decrease of 65% to an increase of 37%,
suggesting wide interpatient variability in the rifampicin
effect [39]. Since efavirenz itself induces CYP2B6 (i.e. auto-
induction), it is possible that rifampicin cannot increase
CYP2B6 expression beyond that resulting from chronic
efavirenz exposure. However, it is also important to point
out that other drugs were administered to our patients for
TB therapy in addition to rifampicin that may have con-
founded any effect of rifampicin. For example, it is also
possible that the use of isoniazid with rifampicin in the TB
co-infected patients could have minimized the induction












CYP2A6*9B or *17:  -- + -- + -- + (*P = 0.028)
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Influence of CYP2A6 slow metabolizer genotypes (*9B and/or *17) and
CYP2B6 c.516G→T genotypes on efavirenz mid-dose concentrations
(average of 4-week and 8-week samples).Shown are the P-values from the
two-way ANOVA (including analysis of gene–gene interactions) and post
hoc multiple pair-wise comparisons (Student–Newman–Keuls test)
within genotype groups
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shown to be an inhibitor of cytochrome P450 in vitro
[40–42]
We recognize that our study has several limitations.
First, the size of the study population was small, as there
were six or fewer patients each with CYP2B6 983T→C or
CYP2A6*9B variants, limiting our ability to detect small
treatment and genotype effects. Second, we were unable
to assess efavirenz concentrations before or after rifampi-
cin treatment to exclude the effect of differences in popu-
lation on the analysis. Third, patients self-administered the
evening dose and so the exact timing of the mid-dose
pharmacokinetic sample (relative to dose) could have dif-
fered between patients.
Despite the above limitations, our findings demon-
strate that in addition to the strong predictive value of
CYP2B6 516G→T polymorphism, CYP2A6 genetic variation
is an independent determinant of efavirenz plasma con-
centrations. If confirmed in larger studies, CYP2A6 geno-
typing could be a useful adjunct to CYP2B6 genotyping for
the prediction of efavirenz concentrations in HIV-infected
patients.
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